Compare PCG & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCG | GEHC |
|---|---|---|
| Founded | 1995 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Computer Software: Prepackaged Software |
| Sector | Utilities | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0B | 29.1B |
| IPO Year | 2000 | 2022 |
| Metric | PCG | GEHC |
|---|---|---|
| Price | $13.03 | $69.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 21 |
| Target Price | $18.50 | ★ $82.70 |
| AVG Volume (30 Days) | ★ 33.2M | 3.5M |
| Earning Date | 10-22-2026 | 10-28-2026 |
| Dividend Yield | ★ 1.54% | 0.23% |
| EPS Growth | 2.61 | ★ 4.84 |
| EPS | 0.72 | ★ 0.85 |
| Revenue | ★ $24,935,000,000.00 | $20,625,000,000.00 |
| Revenue This Year | $4.77 | $5.32 |
| Revenue Next Year | $3.88 | $4.60 |
| P/E Ratio | ★ $18.01 | $82.82 |
| Revenue Growth | 2.11 | ★ 4.84 |
| 52 Week Low | $11.77 | $58.75 |
| 52 Week High | $19.16 | $89.77 |
| Indicator | PCG | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 45.88 | 61.48 |
| Support Level | $12.59 | $68.88 |
| Resistance Level | $13.69 | $72.77 |
| Average True Range (ATR) | 0.37 | 1.62 |
| MACD | 0.21 | 0.71 |
| Stochastic Oscillator | 66.49 | 79.89 |
PG&E is a holding company whose main subsidiary is Pacific Gas and Electric, a regulated utility operating in Central and Northern California that serves 5.3 million electricity customers and 4.6 million gas customers in 47 of the state's 58 counties. PG&E operated under bankruptcy court supervision in 2001-04 during California's energy crisis and in 2019-20 due to wildfire losses. In 2004, PG&E sold its unregulated assets as part of its first postbankruptcy reorganization.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).